Fig. 4From: Sequential intravenous allogeneic mesenchymal stromal cells as a potential treatment for thromboangiitis obliterans (Buerger’s disease)Walking Impairment Questionnaire (WIQ) and European Quality of Life–5 dimensions (EQ-5D) scores before and 5 months after intravenous allogeneic mesenchymal stromal cell (MSC) infusions. DS descriptive system, VAS visual analogue scaleBack to article page